Uveitis Clinical Trial
Official title:
Immunogenetic Mechanisms in Behcet's Disease
Background:
- Uveitis, the inflammation of the interior of the eye, is responsible for numerous new cases
of legal blindness every year. Uveitis can be caused by Beh(SqrRoot)(Beta)et s disease (BD),
a chronic inflammatory disorder that can affect the eye, mucous membranes, and other body
organs such as the joints, intestinal tract, blood vessels, and central nervous system.
Objectives:
The purpose of this study is to see how genes affect Beh(SqrRoot)(Beta)et s disease and if
there are differences in Beh(SqrRoot)(Beta)et s disease among people of different
backgrounds.
Eligibility:
- Individuals who have a diagnosis of BD and are enrolled in another NIH study.
- Individuals who are willing to donate blood for the purposes of this research study and
who are willing to have their blood stored for possible future/other research purposes.
Design:
- As part of the study, blood samples will be drawn from participants when an exacerbation
in disease activity occurs and before and after any significant change in treatment for
BD.
- No treatments will be provided in this study.
Uveitis is responsible for approximately 30,000 cases of new legal blindness in the United
States and 2.8-10% of all cases of blindness. Beh(SqrRoot)(Beta)et s disease (BD) is a
chronic relapsing multisystem inflammatory disorder of unknown etiology that is characterized
by intraocular inflammation, oral and mucosal ulcerations, cutaneous lesions and inflammation
that may affect other body organs such as the joints, intestinal tract, epididymis, blood
vessels and the central nervous system (2). The need for a safer and more effective therapy
for patients with ocular manifestations of BD refractory to or intolerant of systemic
immunosuppressive therapy warrants further investigation. Reports define a specific role for
interleukin (IL)-17A in the pathogenesis of Beh(SqrRoot)(Beta)et s disease.
This protocol will evaluate immune mediators including cytokine profiles (soluble and
intracellular), lymphocyte phenotyping and regulatory T-cells in participants with BD.
Epigenetic modifications will also be studied.
Additionally, it has been suggested that American/Western BD patients may have different
disease characteristics than their Mediterranean counterparts. The disease characteristics of
American/Western and Mediterranean BD patients will be compared and evaluated. Blood samples
from BD participants that have participated in other NIH protocols where participants
consented for other or future use of samples has been obtained will be collected
(particularly from current participants of NIH protocol 03-AR-0173 in which NEI is a
collaborator). In summary, the results will be analyzed with respect to disease in different
ethnic groups, and clinical features of the disease (e.g., ocular vs. non-ocular involvement,
active vs. quiescent disease).
Anonymous blood samples (matched for race, age and sex) will be obtained from the NIH
clinical center (CC) blood bank and will be compared to the diseased samples.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04101604 -
Biomarkers of Common Eye Diseases
|
||
Active, not recruiting |
NCT04704609 -
Imaging Quantification of Inflammation (IQI)
|
||
Completed |
NCT03173144 -
Chronic Inflammatory Disease, Lifestyle and Treatment Response
|
||
Withdrawn |
NCT01280669 -
Intravitreal Sirolimus as Therapeutic Approach to Uveitis
|
Phase 2 | |
Terminated |
NCT02907814 -
Measurement of Anterior Chamber Cell Grading Using Ocular Coherence Tomography
|
N/A | |
Active, not recruiting |
NCT02252328 -
Use of Simvastatin as a Steroid Sparing Agent for Uveitis Patients
|
Phase 2/Phase 3 | |
Completed |
NCT04183387 -
Simvastatin in Uveitis
|
Phase 2 | |
Completed |
NCT01983488 -
Clinical Outcome in Uveitis
|
||
Withdrawn |
NCT00499551 -
A Phase I/IIa Study for the Treatment of Uveitis With Iontophoresis
|
Phase 1/Phase 2 | |
Terminated |
NCT00114062 -
Study to Treat Uveitis Associated Macular Edema
|
Phase 2 | |
Completed |
NCT00476593 -
Retinal OCT and (mfERG) Related to Age, Sex, and the Use of Anti-inflammatory Medications
|
N/A | |
Completed |
NCT00132691 -
Multicenter Uveitis Steroid Treatment (MUST) Trial
|
Phase 4 | |
Completed |
NCT00001867 -
Effect of Pregnancy on Uveitis
|
N/A | |
Completed |
NCT00379275 -
Eye and Immunogenetic Features of Sarcoidosis
|
N/A | |
Active, not recruiting |
NCT03828019 -
Adalimumab vs. Conventional Immunosuppression for Uveitis Trial
|
Phase 3 | |
Terminated |
NCT01939691 -
Macular Edema Nepafenac vs. Difluprednate Uveitis Trial
|
Phase 4 | |
Active, not recruiting |
NCT03889860 -
Objective Choroidal Thickness Measurements in Uveitis
|
||
Completed |
NCT00070759 -
Daclizumab to Treat Non-Infectious Sight-Threatening Uveitis
|
Phase 2 | |
Recruiting |
NCT05486468 -
The Use of Two YUTIQ Versus Sham for Treatment of Chronic Non Infectious Intraocular Inflammation Affecting the Posterior Segment
|
Phase 3 | |
Active, not recruiting |
NCT05385757 -
UNICORNS: Uveitis in Childhood Prospective National Cohort Study
|